Literature DB >> 27770251

The role of endobronchial ultrasonography for mediastinal lymphadenopathy in cases with extrathoracic malignancy.

Kemal Can Tertemiz1, Aylin Ozgen Alpaydin2, Volkan Karacam3.   

Abstract

INTRODUCTION: Many extrathoracic malignancies can metastasize to lungs and mediastinal lymph nodes. Whether mediastinal lesions are metastasis in these patients changes staging, prognosis, and treatment strategy. In this study, we aimed to find out the contribution of EBUS-TBNA to the diagnosis in cases with extrathoracic malignancy.
MATERIALS AND METHODS: Patients who had been previously diagnosed as extrapulmonary solid organ malignancy and in whom mediastinal or hilar lymphadenopathy developed during their follow-up and EBUS-TBNA was applied for diagnostic purposes were retrospectively included in this study.
RESULTS: A total of 91 patients consisting of 35 females (38.5 %) and 56 males (61.5 %) were included in the study. The mean age of the patients was 60.5 (±11.4). Malignancy was not observed in 54 (59.3 %) patients; primary malignancy metastasis was detected in 33 (36.3 %) patients, and primary lung cancer was detected in 4 (4.4 %) patients with EBUS-TBNA. The sensitivity of EBUS-TBNA in extrathoracic malignancies was determined as 90.2 %; its specificity was determined as 100 %, its negative predictive value as 92.5 %, its positive predictive value as 100 %, and its diagnostic accuracy as 95.6 %. The highest rate was determined in the left lower paratracheal lymph node when they were examined in terms of malignancy detection rate in lymph node stations.
CONCLUSION: EBUS-TBNA is a minimally invasive method with quite a low complication rate that does not require general anesthesia. It should be the first step method to be used in the diagnosis of mediastinal and hilar lymphadenopathies seen in extrathoracic malignancies since it has high diagnostic accuracy, sensitivity, and specificity. EBUS-TBNA significantly reduces the need for surgical intervention. Further surgical interventions can be planned in patients in whom diagnostic competence is not ensured.

Entities:  

Keywords:  EBUS-TBNA; Extrathoracic malignancy; Hilar lymphadenopathy; Mediastinal

Mesh:

Year:  2016        PMID: 27770251     DOI: 10.1007/s00464-016-5293-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  21 in total

1.  Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.

Authors:  Helmut Huber; Marina Hodolic; Ingrid Stelzmüller; Rainer Wunn; Margit Hatzl; Franz Fellner; Bernd Lamprecht; Domenico Rubello; Patrick M Colletti; Michael Gabriel
Journal:  Nucl Med Commun       Date:  2015-05       Impact factor: 1.690

2.  EBUS-centred versus EUS-centred mediastinal staging in lung cancer: a randomised controlled trial.

Authors:  Hyo Jae Kang; Bin Hwangbo; Geon-Kook Lee; Byung-Ho Nam; Hyun-Sung Lee; Moon Soo Kim; Jong Mog Lee; Jae Ill Zo; Hee Seok Lee; Ji-Youn Han
Journal:  Thorax       Date:  2013-10-30       Impact factor: 9.139

3.  Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer.

Authors:  Kazuhiro Yasufuku; Masako Chiyo; Eitetsu Koh; Yasumitsu Moriya; Akira Iyoda; Yasuo Sekine; Kiyoshi Shibuya; Toshihiko Iizasa; Takehiko Fujisawa
Journal:  Lung Cancer       Date:  2005-09-19       Impact factor: 5.705

4.  Endobronchial ultrasound-guided transbronchial needle aspiration vs conventional transbronchial needle aspiration in the diagnosis of sarcoidosis.

Authors:  Dheeraj Gupta; Devendra S Dadhwal; Ritesh Agarwal; Nalini Gupta; Amanjit Bal; Ashutosh N Aggarwal
Journal:  Chest       Date:  2014-09       Impact factor: 9.410

5.  Endobronchial ultrasound-guided transbronchial needle biopsy for M1 staging of extrathoracic malignancies.

Authors:  K G Tournoy; E Govaerts; T Malfait; C Dooms
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

6.  Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer.

Authors:  Sang-Won Um; Hong Kwan Kim; Sin-Ho Jung; Joungho Han; Kyung Jong Lee; Hye Yun Park; Yong Soo Choi; Young Mog Shim; Myung-Ju Ahn; Keunchil Park; Yong Chan Ahn; Joon Young Choi; Kyung Soo Lee; Gee Young Suh; Man Pyo Chung; O Jung Kwon; Jhingook Kim; Hojoong Kim
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

Review 7.  Endobronchial ultrasound-guided transbronchial needle biopsy for the diagnosis of intrathoracic lymph node metastases from extrathoracic malignancies: a meta-analysis and systematic review.

Authors:  Bo Yang; Fang Li; Weiwei Shi; Hui Liu; Shengjie Sun; Guoqing Zhang; Shunchang Jiao
Journal:  Respirology       Date:  2014-06-17       Impact factor: 6.424

8.  The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer.

Authors:  Valerie W Rusch; Hisao Asamura; Hirokazu Watanabe; Dorothy J Giroux; Ramon Rami-Porta; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2009-05       Impact factor: 15.609

9.  Endobronchial ultrasound-guided transbronchial needle biopsy for diagnosis of mediastinal lymphadenopathy in patients with extrathoracic malignancy.

Authors:  Jinkyeong Park; Se Jin Jang; Young Soo Park; Yeon-Mok Oh; Tae Sun Shim; Woo Sung Kim; Chang Min Choi
Journal:  J Korean Med Sci       Date:  2011-01-24       Impact factor: 2.153

10.  Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of intrathoracic lymph node metastases from extrathoracic malignancies.

Authors:  Jose Sanz-Santos; Beatriz Cirauqui; Estefania Sanchez; Felipe Andreo; Pere Serra; Eduard Monso; Eva Castellà; Mariona Llatjós; Miguel Mesa; Juan Ruiz-Manzano; Rafael Rosell
Journal:  Clin Exp Metastasis       Date:  2012-11-30       Impact factor: 5.150

View more
  1 in total

Review 1.  Convex probe endobronchial ultrasound: historical, contemporary, and cutting-edge applications.

Authors:  Sameer K Avasarala; Carlos Aravena; Francisco A Almeida
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.